Cowen analyst Tyler Van Buren initiated coverage of BridgeBio with an Outperform rating. The firm thinks "significant" near-term upside could be realized if infigratinib in children with achondroplasia works and if BBP-711 in healthy volunteers hits in Part B of its trial. BridgeBio’s $1.7B of debt "adds risk," but "the reward will be significant if successful," the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BBIO:
- Fly Insider: Travelzoo, Box among week’s notable insider trades
- BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
- BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
- BridgeBio initiates Phase 3 trial CALIBRATE study of encaleret
Questions or Comments about the article? Write to editor@tipranks.com